Unknown

Dataset Information

0

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.


ABSTRACT: Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating the safety, tolerability, and efficacy of NBI-98854 for the treatment of tardive dyskinesia.Male and female adult subjects with moderate or severe tardive dyskinesia were included. NBI-98854 or placebo was given once per day starting at 25 mg and then escalated by 25 mg to a maximum of 75 mg based on dyskinesia and tolerability assessment. The primary efficacy endpoint was the change in Abnormal Involuntary Movement Scale from baseline at week 6 scored by blinded, central video raters. The secondary endpoint was the Clinical Global Impression of Change-Tardive Dyskinesia score assessed by the blinded investigator.Two hundred five potential subjects were screened, and 102 were randomized; 76% of NBI-98854 subjects and 80% of placebo subjects reached the maximum allowed dose. Abnormal Involuntary Movement Scale scores for NBI-98854 compared with placebo were significantly reduced (p = 0.0005). Active drug was also superior on the Clinical Global Impression of Change-Tardive Dyskinesia (p < 0.0001). Treatment-emergent adverse event rates were 49% in the NBI-98854 and 33% in the placebo subjects. The most common adverse events (active vs. placebo) were fatigue and headache (9.8% vs. 4.1%) and constipation and urinary tract infection (3.9% vs. 6.1%). No clinically relevant changes in safety assessments were noted.NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.

SUBMITTER: O'Brien CF 

PROVIDER: S-EPMC5049616 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

O'Brien Christopher F CF   Jimenez Roland R   Hauser Robert A RA   Factor Stewart A SA   Burke Joshua J   Mandri Daniel D   Castro-Gayol Julio C JC  

Movement disorders : official journal of the Movement Disorder Society 20150908 12


<h4>Background</h4>Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel, highly selective, vesicular monoamine transporter 2 inhibitor. We present results of a randomized, 6-week, double-blind, placebo-controlled, dose-titration study evaluating the safety, tolerability, and efficacy of NBI-98854 for the treatment of tardive dyskinesia.<h4>Methods</h4>Male and female adult subjects with moderate or severe tardive dyskinesia were inclu  ...[more]

Similar Datasets

| S-EPMC5475908 | biostudies-literature
| S-EPMC8689140 | biostudies-literature
| S-EPMC9826124 | biostudies-literature
| S-EPMC5475778 | biostudies-literature
| S-EPMC6591749 | biostudies-literature
| S-EPMC4255169 | biostudies-other
| S-EPMC6040721 | biostudies-other
| S-EPMC3338072 | biostudies-literature
| S-EPMC7193905 | biostudies-literature
| S-EPMC3825689 | biostudies-literature